CALL TOLL FREE 1-800-732-7985

Chronic obstructive pulmonary disease (COPD) is very common leading to frequent physician visits and hospitalizations and become the 3rd leading cause of death in the U.S. COPD is the only major disease among the top 10 that continues to increase. Because of the long pre-clinical period, signs and symptoms of COPD develop predominantly in older adults.

Sleep-related disorders are most prevalent in adults and are associated with increased mortality and morbidity from obesity, cardiovascular diseases, diabetes, and depression, resulting in reduced quality of life (QOL) and increased health care costs. Patients with severe COPD commonly exhibit abnormal sleep like insomnia contributing to chronic fatigue, daytime sleepiness. Additionally, medications used to treat COPD, such albuterol or prednisone may affect sleep quality. A nocturnal reduction of nocturnal oxygen levels commonly seen in patients with COPD can have profound effects and contribute to long-term sequelae, producing arrhythmias, myocardial stress, and, possibly, lower survival.

Sleep apnea (OSA) is a chronic medical condition where the affected person repeatedly stops or nearly stops breathing during sleep. These episodes last 10 seconds or more and cause oxygen levels in the blood to drop leading to important health consequences. Usually it is caused by obstruction of the upper airway, resulting in obstructive sleep apnea. However, it may be caused also by a failure of the brain to initiate a breath, called central sleep apnea. OSA is very common, especially in older adults, occurring in up to 70% of men and 56% of women. Patients with untreated OSA have more automobile accidents and suffer from more family and social discord. Other important risk factors associated with OSA include smoking and alcohol. The symptoms of obstructive sleep apnea include loud snoring and/or abnormal pattern of snoring with pauses and gasps. Other symptoms include excessive daytime sleepiness, memory changes, depression, erectile dysfunction and irritability. OSA occurs in about 10 to 15% of patients with COPD, a condition referred to as the “overlap syndrome”. Although the prevalence of OSA is similar in patients with COPD as in the general population, individuals with both conditions without CPAP treatment have an increased risk of death and more hospitalizations from acute exacerbations.

Effective available treatments for OSA include continuous nasal airway pressure devices (e.g., CPAP); a mask is worn over the nose during sleep while compressed air is gently forced through the nose to keep the airway open. Different patients need different mask sizes and different pressure levels for optimal treatment results.

Oxygen therapy is used for low nocturnal oxygen levels and, medications such as non-benzodiazepines and behavioral therapy are current treatments for insomnia. Another type of treatment for obstructive sleep apnea is surgery to correct obstructions in the airways. The most common surgery is called UPPP, for uvulopalatopharngyoplasty. This surgery removes tissue from the rear of the mouth and top of the throat. The tissues removed include parts of the uvula (the flap of tissue that hangs down at the back of the mouth), the soft palate, and the pharynx. Tonsils and adenoids are usually removed in this operation. Surgical interventions are sometimes considered but are rarely successful. Another approach to treating OSA involves the use of oral appliances intended to improve breathing either by holding the tongue in place or by pushing the lower jaw forward during sleep to increase the air volume in the upper airway. In treating insomnia in COPD, benzodiazepines such diazepam should be avoided. However, newer compounds, such as zolpidem, may be safer in less severe COPD. Melatonin agonists can also be used. Cognitive behavior therapy is still considered the primary first-line treatment for insomnia, but has not yet been studied in COPD.

Exercise has been demonstrated to improve sleep in epidemiological studies. In a prospective study of 86 patients with chronic lung diseases referred to the UCSD pulmonary rehabilitation program (PR), we demonstrated a significant improvement in sleep quality after pulmonary rehabilitation measured with the Pittsburgh Sleep Quality Index (PSQI), a well-validated measure of overall sleep quality. Further studies to better characterize sleep-related disorders among COPD are under way.

In conclusion, sleep is poor in COPD patients and sleep disorders such OSA have profound effects on this population. Prediction of the patients diagnosed of COPD who are at risk for sleep difficult but crucial because their clinical implications. Therefore, increase public awareness about this serious condition is of paramount importance. Clinicians should include sleep evaluation in patients diagnosed of COPD asking about daytime sleepiness, snoring, pauses while sleeping and insomnia symptoms, referring to the specialist when necessary to address treatment options of comorbid sleep disturbances, which may provide significant long-term benefit for such patients.

1. Diaz-Guzman, E., Mannino, D.M. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:7–16
2. McSharry, D.G., Ryan, S., Calverley, P. et al, Sleep quality in chronic obstructive pulmonary disease. Respirology. 2012;17:1119–1124
3. Valipour, A., Lavie, P., Lothaller, H. et al, Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12:367–372
4. Agusti, A., Hedner, J., Marin, J.M. et al, Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20:183–194
5. Omachi, T.A., Blanc, P.D., Claman, D.M. et al, Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–483
6. Tsai, S.C., Lee-Chiong, T. Lung hyperinflation and sleep quality in the overlap syndrome. COPD. 2009;6:419–420
7. Collop, N. Sleep and sleep disorders in chronic obstructive pulmonary disease. Respiration. 2010;80:78–86
8. Lewis, C.A., Fergusson, W., Eaton, T. et al, Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax. 2009;64:133–138
9. McNicholas, W.T. Impact of sleep in COPD. Chest. 2000;117:48S–53S
10.Sanders, M.H., Newman, A.B., Haggerty, C.L. et al, Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med. 2003;167:7–14
11.Steveling, E.H., Clarenbach, C.F., Miedinger, D. et al, Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2014;88:451–457
12.Greenberg-Dotan, S., Reuveni, H., Tal, A. et al, Increased prevalence of obstructive lung disease in patients with obstructive sleep apnea.  Sleep Breath. 2014;18:69–75
13.He, B.-T., Lu, G., Xiao, S.-C. et al, Coexistence of OSA may compensate for sleep related reduction in neural respiratory drive in patients with COPD. Thorax. 2017;72:256–262
14.Soler X et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(8): 1219-25. dos: 10.1513/AnnalsATS.201407-336OC
15.Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med, 6 (1985), pp. 51–610
16.Soler-Cataluna JJ et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925-931.
17.Trask CH, Cree EM. Oximeter studies on patients with chronic obstructive emphysema, awake and during sleep. N Engl J Med 1962;266:639-642.
18.Owens RL and Malhotra A. Sleep-disordered breathing and COPD: The overlap syndrome. Resp Care 2010;55(10): 1333-1346
19.Marin JM et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome Am J Respir Crit Care Med 2010 Aug 1;182(3):325-31. doi: 10.1164/rccm.200912-1869OC. Epub
20.Lavie P et al. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 1995;18(3):149-157
21.Stanchina ML et al. Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med 2013 Aug 15;9(8):767-72. doi: 10.5664/jcsm.2916.
22.Machado MC et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010 Jan;35(1):132-7. doi: 10.1183/09031936.00192008. Epub 2009 Jul 2.
23.Toraldo DM et al. Fixed-pressure nCPAP in patients with obstructive sleep apnea (OSA) syndrome and chronic obstructive pulmonary disease (COPD): a 24-month follow-up study. Sleep Breath 2010 Jun;14(2):115-23. doi:
24.Mansfield D et al. Effects of continuous positive airway pressure on lung function in patients with chronic obstructive pulmonary disease and sleep disordered breathing. Respirology 1999  Dec;4(4):365-70.
25.Bhatt SP et al. Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. Int J Chron Obstruct Pulmon Dis 2013; 8: 581–589. Published online 2013 Nov 22. doi: 10.2147/COPD.S53619
26.Global Alliance Against Chronic Respiratory Diseases (GARD). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach.
27.Global initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis. Management, and Prevention of Chronic Obstructive Pulmonary Disease.
28.Fletcher MJ et al. COPD Uncovered: An International survey on the impact of chronic obstructive pulmonary disease (COPD) on a working age population.
29.Murray CJL et al. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997:349:1498-1504.

Happy Easter! We will be closed from April 19th to April 22nd and will reopen on April 23rd at 9:00AM but our Burnaby and Vancouver locations will be open on Saturday, April 20. All orders will be processed on April 23rd. Please email us at if you have any questions. Thank you! Dismiss